Ranbaxy, Teva To Appeal Injunction Against Accupril Generics

Law360, New York (March 30, 2005, 12:00 AM EST) -- Indian drug maker Ranbaxy Laboratories Ltd. and Israeli partner Teva Pharmaceuticals have vowed to file an immediate appeal of a New Jersey federal court’s preliminary injunction against sales of a generic version of Pfizer’s hypertension drug Accupril.

“While Teva and Ranbaxy will comply with the preliminary injunction, they also will immediately file with the U.S. Court of Appeals for the Federal Circuit an appeal to have the injunction lifted and a motion to expedite the appeal,” said Jay Deshmukh, Ranbaxy's Vice President for Intellectual Property....
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.